3M Company vs Viatris Inc — how do they compare? 3M Company trades at $183.32 (market cap $94.44B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: 3M Company is far larger — about 5.1× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| MMM | VTRS | |
|---|---|---|
Market Cap | $94.44B | $18.69B |
Sector | Industrials | Health |
52-Week High | $183.13 | $17.86 |
52-Week Low | $141.10 | $9.49 |
Enterprise Value | $103.67B | $30.80B |
Dividend Yield | 1.7% | 2.95% |
Signals from Pluang's Aura AI — not financial advice
3M (MMM) trades at $184.15, up 1.16% on the day, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings, beating estimates and raising full-year guidance, driven by growth in Safety & Industrial and Transport & Electronics segments. Financial health is solid with a net income margin of 11.9% and robust cash flow, though valuation ratios like P/E of 32.53 appear elevated. Recent news highlights innovation in high-growth verticals and a partnership with Microsoft on EBO technology.
The outlook for MMM is positive due to operational improvements and raised guidance, but risks include high valuation, ongoing litigation, and macroeconomic pressures. Analyst sentiment is mixed with a consensus price target of $173.00 below the current price, suggesting cautious optimism. Investors should weigh strong fundamentals against potential headwinds for balanced decision-making.
Viatris (VTRS) trades at $16.105, down 1.07% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates with EPS of $0.69 and revenue growth of 5%, but the company posted a net loss of $3.51B in 2025. Positive developments include FDA approval for Gwyn Lo and a raised 2026 outlook, though debt remains elevated at $14.04B long-term.
Outlook is cautious; while operational cash flow is strong at $2.32B and dividends provide income, persistent net losses and high P/E of 236.2 signal overvaluation risks. Analyst consensus leans Hold (61.54%), with upside potential if turnaround gains traction, but investors face headwinds from generic drug pricing pressures and execution challenges.
Trailing returns across standard periods
Latest headlines on both assets
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →